

# Yves Chalandon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2079822/publications.pdf>

Version: 2024-02-01

152  
papers

5,194  
citations

117453

34  
h-index

98622

67  
g-index

159  
all docs

159  
docs citations

159  
times ranked

6530  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. <i>Haematologica</i> , 2022, 107, 1054-1063.	1.7	20
2	Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 23-30.	1.3	4
3	Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation. <i>Pharmacogenomics Journal</i> , 2022, 22, 9-18.	0.9	1
4	Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab596.	0.4	12
5	Rhinovirus Infections among Hematopoietic Stem Cell Transplant Recipients: A Pre-Transplant Dilemma?. <i>Viruses</i> , 2022, 14, 267.	1.5	7
6	Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors – first 10 years of prospective donor follow-up of Swiss donors. <i>Bone Marrow Transplantation</i> , 2022, 57, 918-924.	1.3	4
7	Frequency and causes of antifungal treatment changes in allogeneic haematopoietic cell transplant recipients with invasive mould infections. <i>Mycoses</i> , 2022, 65, 199-210.	1.8	2
8	Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1072-1078.	1.3	4
9	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1421-1427.	1.3	7
10	Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 67.e1-67.e7.	0.6	1
11	Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial. <i>Annals of Hematology</i> , 2021, 100, 209-216.	0.8	13
12	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. <i>Cancers</i> , 2021, 13, 672.	1.7	7
13	Thiotepa+busulfan+fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1593-1602.	1.3	8
14	Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Société Française de Greffe de Moelle et de Thérapie cellulaire (SFGM-TC) multicentre cohort study. <i>British Journal of Haematology</i> , 2021, 192, e121-e124.	1.2	36
15	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1944-1952.	1.3	7
16	Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study. <i>Vaccines</i> , 2021, 9, 372.	2.1	22
17	Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	5
18	Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 771-776.	1.3	13

#	ARTICLE	IF	CITATIONS
19	The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft. <i>Bone Marrow Transplantation</i> , 2021, 56, 2284-2286.	1.3	0
20	Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience. <i>Mycopathologia</i> , 2021, 186, 775-788.	1.3	5
21	Successful treatment of central nervous system lymphoproliferative disorder in a kidney-pancreas and stem cell transplanted patient using intrathecal rituximab. <i>BMJ Case Reports</i> , 2021, 14, e238236.	0.2	3
22	Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 3094-3096.	1.3	28
23	Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation. <i>Blood Advances</i> , 2021, 5, 3377-3386.	2.5	7
24	GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	4
25	Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 811.	1.5	2
26	Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. <i>Medical Mycology</i> , 2021, 59, 701-711.	0.3	8
27	Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2. <i>Blood</i> , 2021, 138, 1232-1232.	0.6	10
28	Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP – EBMT study. <i>British Journal of Haematology</i> , 2020, 188, 745-756.	1.2	20
29	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 936-942.	2.0	15
30	Comparing Dried Blood Spots and Plasma Concentrations for Busulfan Therapeutic Drug Monitoring in Children. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 111-117.	1.0	13
31	Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP. <i>European Journal of Haematology</i> , 2020, 104, 181-189.	1.1	7
32	Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2020, 34, 1422-1432.	3.3	20
33	Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 920-927.	2.0	11
34	Optimal Treatment Duration of <i>Pseudomonas aeruginosa</i> Infections in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa246.	0.4	7
35	Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. <i>Blood Advances</i> , 2020, 4, 3699-3707.	2.5	17
36	Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. <i>Blood Advances</i> , 2020, 4, 4267-4277.	2.5	14

#	ARTICLE	IF	CITATIONS
37	Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFR $\alpha$ positive myeloid neoplasm. <i>Leukemia and Lymphoma</i> , 2020, 61, 2226-2229.	0.6	1
38	Torque Teno Virus as a Potential Biomarker for Complications and Survival After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 998.	2.2	25
39	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020, 38, 1518-1526.	0.8	34
40	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. <i>Leukemia</i> , 2020, 34, 1730-1740.	3.3	21
41	Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. <i>Leukemia</i> , 2020, 34, 1751-1759.	3.3	18
42	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study. <i>Transplant Infectious Disease</i> , 2020, 22, e13289.	0.7	11
43	Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study. <i>Blood</i> , 2020, 136, 328-338.	0.6	23
44	Intracellular Pathogen in the Cerebrospinal Fluid of an Allogeneic Hematopoietic Cell Transplant Recipient With Graft-Versus-Host Disease and Brain Lesions. <i>Clinical Infectious Diseases</i> , 2020, 71, 3005-3008.	2.9	0
45	Human pegivirus persistence in human blood virome after allogeneic haematopoietic stem-cell transplantation. <i>Clinical Microbiology and Infection</i> , 2019, 25, 225-232.	2.8	28
46	Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2366-2374.	2.0	3
47	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2008-2016.	2.0	20
48	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2167-2171.	2.0	69
49	Epigenetic Silencing Affects Asparaginase Sensitivity and Predicts Outcome in T-ALL. <i>Clinical Cancer Research</i> , 2019, 25, 2483-2493.	3.2	25
50	Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. <i>Haematologica</i> , 2019, 104, 1230-1236.	1.7	12
51	Dynamics of Expression of Programmed Cell Death Protein-1 (PD-1) on T Cells After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 1034.	2.2	39
52	State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. <i>Haematologica</i> , 2019, 104, 659-668.	1.7	56
53	High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1701-1709.	1.3	15
54	Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Haematologica</i> , 2019, 104, 1782-1788.	1.7	48

#	ARTICLE	IF	CITATIONS
55	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1981-1988.	2.5	12
56	DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT-LWP STUDY. <i>Hematological Oncology</i> , 2019, 37, 316-317.	0.8	0
57	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 522-528.	2.0	48
58	Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1022-1028.	1.3	19
59	PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. <i>Blood</i> , 2019, 133, 280-284.	0.6	48
60	Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2019, 134, 3335-3335.	0.6	1
61	Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial. <i>Blood</i> , 2019, 134, 1295-1295.	0.6	4
62	Myeloproliferative Neoplasms. , 2019, , 569-578.		1
63	Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2018, 53, 1072-1075.	1.3	0
64	Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon- $\beta$ . <i>Oncologist</i> , 2018, 23, 719-721.	1.9	13
65	Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2018, 59, 590-600.	0.6	3
66	Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. <i>Cancer Epidemiology</i> , 2018, 52, 55-62.	0.8	8
67	Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 84-92.	1.0	22
68	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2514-2523.	0.8	99
69	Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study. <i>Transplant Infectious Disease</i> , 2018, 20, e12981.	0.7	35
70	Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. <i>British Journal of Haematology</i> , 2018, 182, 418-422.	1.2	28
71	Central nervous system graft-versus-host disease (CNS-CvHD) after allogeneic haematopoietic stem cell transplantation. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-221840.	0.2	13
72	Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016. <i>Swiss Medical Weekly</i> , 2018, 148, w14589.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 470-472.	0.6	2
74	FLT3-ITD mutations do not impact the outcome of patients allografted with partial T-cell depleted grafts for AML with normal cytogenetics in first complete remission. <i>Hematological Oncology</i> , 2017, 35, 392-394.	0.8	0
75	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. <i>Blood</i> , 2017, 129, 1636-1645.	0.6	77
76	Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient. <i>International Journal of Infectious Diseases</i> , 2017, 55, 24-26.	1.5	12
77	Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2017, 177, 759-765.	1.2	38
78	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2017, 130, 1832-1844.	0.6	66
79	The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Pharmacology</i> , 2017, 8, 451.	1.6	8
80	TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature. <i>Frontiers in Medicine</i> , 2017, 4, 149.	1.2	30
81	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. <i>Oncotarget</i> , 2017, 8, 90852-90867.	0.8	39
82	Improvement of Relative Survival in Elderly Patients with Acute Myeloid Leukemia Emerging from Population-Based Cancer Registries in Switzerland from 2001-2013. <i>Blood</i> , 2017, 130, 863-863.	0.6	0
83	A Protective Role of DNA Repair Genes Against Acute Graft Versus Host Disease in Children. <i>Blood</i> , 2017, 130, 749-749.	0.6	0
84	Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2016, 7, 362.	2.2	55
85	Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1615-1620.	2.0	46
86	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 1044-1053.	13.9	270
87	Torque teno virus in patients undergoing allogeneic hematopoietic stem cell transplantation for hematological malignancies. <i>Bone Marrow Transplantation</i> , 2016, 51, 440-442.	1.3	37
88	Excellent outcome with a high proportion of mixed chimerism in patients with severe aplastic anemia treated with partially T-cell-depleted peripheral hematopoietic stem cell transplants. <i>Bone Marrow Transplantation</i> , 2016, 51, 860-862.	1.3	4
89	Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. <i>Bone Marrow Transplantation</i> , 2016, 51, 955-960.	1.3	6
90	Efficient Prophylaxis with Defibrotide for Sinusoidal Obstruction Syndrome (SOS) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2016, 128, 2204-2204.	0.6	6

#	ARTICLE	IF	CITATIONS
91	Epidemiology of Bacterial Infections during Induction Chemotherapy in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Analysis of the Graall-2005 Study. <i>Blood</i> , 2016, 128, 2777-2777.	0.6	2
92	Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2016, 128, 3499-3499.	0.6	2
93	Reactive Hemophagocytic Syndrome after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). <i>Blood</i> , 2016, 128, 4617-4617.	0.6	1
94	An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2016, 128, 628-628.	0.6	1
95	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. <i>Blood</i> , 2016, 128, 762-762.	0.6	13
96	Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.. <i>Blood</i> , 2016, 128, 522-522.	0.6	0
97	Family Mismatched Donor Transplantation for Myelofibrosis: A Retrospective Analysis of the EBMT Chronic Leukaemia Working Party. <i>Blood</i> , 2016, 128, 4655-4655.	0.6	1
98	Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT. <i>Blood</i> , 2016, 128, 4685-4685.	0.6	2
99	Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 2486-2496.	0.6	233
100	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015, 171, 239-246.	1.2	80
101	NK Cell Functional Impairment after Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Reduced Levels of T-bet and Eomesodermin. <i>Journal of Immunology</i> , 2015, 195, 4712-4720.	0.4	31
102	Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies. <i>Bone Marrow Research</i> , 2015, 2015, 1-6.	1.7	9
103	Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies. <i>Bone Marrow Research</i> , 2015, 2015, 1-7.	1.7	8
104	Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2015, 50, 790-794.	1.3	15
105	E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. <i>Journal of Infectious Diseases</i> , 2015, 212, 1726-1734.	1.9	54
106	Complete and sustained remission of spondyloarthritis after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome. <i>Joint Bone Spine</i> , 2015, 82, 216-217.	0.8	7
107	High-resolution HLA matching in unrelated donor transplantation in Switzerland: differential impact of class I and class II mismatches may reflect selection of nonimmunogenic or weakly immunogenic DRB1/DQB1 disparities. <i>Bone Marrow Transplantation</i> , 2015, 50, 1201-1205.	1.3	15
108	Suggestive evidence of a role of HLA-DRB4 mismatches in the outcome of allogeneic hematopoietic stem cell transplantation with HLA-10/10-matched unrelated donors: a French-Swiss retrospective study. <i>Bone Marrow Transplantation</i> , 2015, 50, 1316-1320.	1.3	18

#	ARTICLE	IF	CITATIONS
109	Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 3711-3719.	0.6	291
110	Post-artesunate delayed haemolysis â€™ report of four cases and review of the literature. <i>Swiss Medical Weekly</i> , 2015, 145, w14181.	0.8	11
111	Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. <i>Haematologica</i> , 2014, 99, 1492-1498.	1.7	19
112	The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2014, 49, 55-61.	1.3	36
113	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 3739-3749.	0.6	281
114	Validation of the Disease Risk Index for Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after T Cell Depletion. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1322-1328.	2.0	13
115	Genetic Determinants of Busulfan Clearance and Outcomes in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation- Result of a Multicentric Prospective Study on Behalf of the Pediatric Disease Working Party of the European Blood and Marrow Transplantation Group. <i>Blood</i> , 2014, 124, 424-424.	0.6	0
116	Value of EVI1 Gene Expression Level in Adult Acute Lymphoblastic Leukemia (ALL): A Study from the Group for Research on Adult ALL (GRAALL). <i>Blood</i> , 2014, 124, 1081-1081.	0.6	18
117	Toward a <i>NOTCH1/FBXW7/RAS/PTEN</i>-Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 4333-4342.	0.8	202
118	Allo-SCT for multiple myeloma in the era of novel agents: a retrospective study on behalf of Swiss Blood SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 408-413.	1.3	6
119	High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3889-3897.	0.8	392
120	Reversible ventricular arrhythmia induced by dasatinib. <i>Clinical Case Reports (discontinued)</i> , 2013, 1, 20-25.	0.2	13
121	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	9
122	Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2012, 47, 236-242.	1.3	22
123	Impact of HLA-DPB1 Haplotypes on Outcome of 10/10 Matched Unrelated Hematopoietic Stem Cell Donor Transplants Depends on MHC-Linked Microsatellite Polymorphisms. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 608-616.	2.0	43
124	High hyperdiploid acute lymphoblastic leukemia in adults shows clonal heterogeneity and chromosomal instability at diagnosis and during the course of the disease. <i>Annals of Hematology</i> , 2012, 91, 793-796.	0.8	3
125	Third-party mesenchymal stromal cell infusion is associated with a decrease in thrombotic microangiopathy symptoms observed post-hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2012, 16, 131-136.	0.5	5
126	Towards a Purely Oncogenetic Risk Classification of Adult T-ALL: a GRAALL Study. <i>Blood</i> , 2012, 120, 881-881.	0.6	0



#	ARTICLE	IF	CITATIONS
127	Do NK Cells Contribute to the Pathophysiology of Transplant-Associated Thrombotic Microangiopathy?. <i>American Journal of Transplantation</i> , 2011, 11, 1748-1752.	2.6	7
128	Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2011, 87, 138-147.	1.1	17
129	Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Severe Aplastic Anemia After Cyclophosphamide Plus Antithymocyte Globulin Conditioning Regimen. <i>Blood</i> , 2011, 118, 4090-4090.	0.6	0
130	CD56 <sup>bright</sup> NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells. <i>European Journal of Immunology</i> , 2010, 40, 3246-3254.	1.6	31
131	Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2010, 45, 558-564.	1.3	56
132	5-Azacytidine to Treat Acute Myeloid Leukemia In Elderly or Frail Patients: A Phase II Study (SAKK 30/07). <i>Blood</i> , 2010, 116, 2181-2181.	0.6	0
133	Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome <sup>+</sup> Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 911-918.	0.8	506
134	Hodgkin <sup>+</sup> lymphoma relapsing after autologous transplantation: allogeneic hematopoietic stem cell transplantation using a strategy of reduced intensity conditioning, and T <sup>+</sup> cell depletion with T <sup>+</sup> cell add <sup>+</sup> back. <i>European Journal of Haematology</i> , 2009, 83, 273-275.	1.1	4
135	Atypical presentation of acute myeloid leukemia: cardiac myeloid sarcoma. <i>International Journal of Hematology</i> , 2009, 89, 693-698.	0.7	16
136	PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. <i>Leukemia</i> , 2009, 23, 1989-1998.	3.3	101
137	Cord blood banks collect units with different HLA alleles and haplotypes to volunteer donor banks: a comparative report from Swiss Blood stem cells. <i>Bone Marrow Transplantation</i> , 2009, 43, 771-778.	1.3	15
138	Long-Term Results of the Imatinib GRAAPH-2003 Study in Newly-Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia... <i>Blood</i> , 2009, 114, 3080-3080.	0.6	7
139	Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. <i>Seminars in Immunopathology</i> , 2008, 30, 425-437.	2.8	210
140	Quality of life and social integration after allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2008, 42, 819-827.	1.3	80
141	Steroid-responsive cauda equina syndrome associated with GVHD after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2008, 41, 315-316.	1.3	5
142	The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable. <i>Bone Marrow Transplantation</i> , 2007, 40, 515-522.	1.3	59
143	Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-Leukemia Reaction? A Prospective Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 102-110.	2.0	47
144	Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland. <i>Bone Marrow Transplantation</i> , 2006, 37, 909-916.	1.3	39

#	ARTICLE	IF	CITATIONS
145	Defibrotide Effectively Prevents Veno-Occlusive Disease of the Liver (VOD) after Allogeneic Stem Cell Transplantation. An Extended Study.. Blood, 2006, 108, 2962-2962.	0.6	0
146	Longitudinal follow-up of body composition in hematopoietic stem cell transplant patients. Bone Marrow Transplantation, 2005, 35, 1171-1177.	1.3	75
147	Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2004, 10, 347-354.	2.0	123
148	Pharmakokinetics of Valganciclovir after AlloSCT: A Fixed Oral Dose Can Be Used for Preemptive Therapy in Patients with Normal Body Weight - Even with Intestinal GVHD.. Blood, 2004, 104, 2239-2239.	0.6	0
149	Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Geneva experience. Leukemia, 2003, 17, 228-231.	3.3	48
150	Benefit of Prestorage Leukocyte Depletion of Single-Donor Platelet Concentrates. Vox Sanguinis, 1999, 76, 27-37.	0.7	18
151	Benefit of prestorage leukocyte depletion of single-donor platelet concentrates. Vox Sanguinis, 1999, 76, 27-37.	0.7	9
152	Kinetics of disappearance and appearance of isoagglutinins A and B after ABO-incompatible hematopoietic stem cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	0